A 62-year-old woman from Mumbai with a history of unopposed estrogen exposure (never used hormone replacement therapy, nulliparous, BMI 31 kg/m²) presents with postmenopausal bleeding. Endometrial biopsy shows grade 3 endometrioid adenocarcinoma. Staging MRI reveals invasion beyond the outer third of the myometrium (stage IIIA) with no cervical stromal involvement or distant metastases. After TAH-BSO and pelvic lymph node dissection, final pathology confirms stage IIIA disease. Pelvic lymph nodes are negative. What is the most appropriate adjuvant treatment?

Explanation

## Clinical Context **Key Point:** This patient has stage IIIA endometrial cancer (deep myoinvasion >2/3 depth) with grade 3 (high-grade) histology. Despite negative pelvic lymph nodes, the combination of deep myoinvasion and high grade places her at high risk for locoregional and distant recurrence. ## Risk Stratification | Risk Factor | Present? | Significance | |-------------|----------|-------------| | Grade 3 histology | Yes | High-grade; increased recurrence risk | | Stage IIIA (deep myoinvasion) | Yes | Extrauterine spread; locoregional recurrence risk | | Negative pelvic nodes | Yes | Favorable; does NOT eliminate need for adjuvant therapy | | Negative para-aortic nodes | Assumed | Favorable for locoregional approach | | Nulliparity + obesity | Yes | Risk factors for aggressive tumor biology | ## Rationale for Correct Answer **External beam pelvic radiation therapy (EBRT) with or without vaginal brachytherapy** is the standard adjuvant approach for stage IIIA endometrial cancer because: 1. **Locoregional control** — EBRT targets the pelvis to reduce vaginal/pelvic recurrence (which is the dominant pattern of failure in stage IIIA) 2. **High-grade histology** — grade 3 tumors have higher propensity for locoregional spread despite negative nodes 3. **Deep myoinvasion** — stage IIIA indicates aggressive local disease warranting locoregional therapy 4. **Evidence-based** — GOG-99 and subsequent trials support EBRT for stage IIIA disease with high-grade histology **High-Yield:** The presence of **negative pelvic lymph nodes does NOT eliminate the need for adjuvant therapy** in stage IIIA, grade 3 endometrial cancer. The stage (IIIA) and grade (3) themselves are sufficient indications for EBRT. **Clinical Pearl:** Vaginal brachytherapy alone is insufficient for stage IIIA disease; EBRT is needed to cover the pelvic sidewall and parametrium where microscopic disease may lurk. Brachytherapy may be added for enhanced vaginal control but does not replace EBRT. ## Treatment Sequencing ```mermaid flowchart TD A[Stage IIIA, Grade 3 Endometrial Cancer]:::outcome --> B{Pelvic Nodes?}:::decision B -->|Positive| C[EBRT + Chemotherapy ± Brachytherapy]:::action B -->|Negative| D[Grade 3?]:::decision D -->|Yes| E[EBRT ± Brachytherapy]:::action D -->|No| F[Brachytherapy alone or observation]:::action E --> G[Consider chemotherapy if high-risk features]:::action ``` **Mnemonic:** **IIIA + Grade 3 = EBRT** (Stage IIIA with high-grade histology mandates external beam radiation). ## Why Other Options Are Incorrect - **Observation alone** — unacceptable for stage IIIA, grade 3 disease; high recurrence risk without adjuvant therapy - **Chemotherapy alone** — not standard for stage IIIA with negative nodes; chemotherapy is reserved for advanced (stage IV) or metastatic disease, or as an adjunct to radiation in very high-risk cases - **Vaginal brachytherapy alone** — insufficient for stage IIIA; does not adequately cover the pelvic sidewall and parametrium where microscopic disease may exist